An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Autolus Therapeutics plc (Nasdaq: AUTL) will announce its first quarter 2024 financial results and operational highlights on May 14, 2024. The company will host a conference call to discuss the results and provide a business update.
Autolus Therapeutics plc (Nasdaq: AUTL) annuncerà i risultati finanziari del primo trimestre del 2024 e gli aggiornamenti operativi il 14 maggio 2024. La compagnia terrà una conferenza telefonica per discutere i risultati e fornire un aggiornamento sulle attività.
Autolus Therapeutics plc (Nasdaq: AUTL) anunciará los resultados financieros del primer trimestre de 2024 y las novedades operativas el 14 de mayo de 2024. La empresa realizará una llamada de conferencia para discutir los resultados y proporcionar una actualización de negocio.
Autolus Therapeutics plc (Nasdaq: AUTL)는 2024년 1분기 재무 결과 및 운영 하이라이트를 2024년 5월 14일에 발표할 예정입니다. 회사는 결과를 논의하고 사업 업데이트를 제공하기 위해 전화 회의를 주최할 것입니다.
Autolus Therapeutics plc (Nasdaq : AUTL) annoncera ses résultats financiers pour le premier trimestre 2024 et les points forts opérationnels le 14 mai 2024. L'entreprise organisera une conférence téléphonique pour discuter des résultats et fournir une mise à jour commerciale.
Autolus Therapeutics plc (Nasdaq: AUTL) wird am 14. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 und betriebliche Höhepunkte bekannt geben. Das Unternehmen wird eine Telefonkonferenz veranstalten, um die Ergebnisse zu diskutieren und ein Geschäftsupdate zu geben.
Positive
None.
Negative
None.
LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2024 financial results and operational highlights before open of US markets on Tuesday, May 14, 2024.
Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a leading biotechnology company focussed on the development and commercialisation of engineered t-cell therapies for haematological and solid tumours. autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient’s own cells.
